Floatz logo

Mrt-2359

L-MYC and N-MYC Amplified Solid Tumors

Monte Rosa Therapeutics, IncPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the L-MYC and N-MYC Amplified Solid Tumors cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Monte Rosa Therapeutics, Inc
Phase 1/2CCC

Same molecule, other indications

Mrt-2359 is also rated in:

neuroendocrine carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →